Cartesian Therapeutics Appoints New Chief Medical Officer
Ticker: RNAC · Form: 8-K · Filed: Apr 1, 2024 · CIK: 1453687
| Field | Detail |
|---|---|
| Company | Cartesian Therapeutics, Inc. (RNAC) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $420,000, $440,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Cartesian Therapeutics just hired a new CMO, Dr. Jonathan F. Miller, from Insmed. Big move for their drug pipeline.
AI Summary
Cartesian Therapeutics, Inc. announced on March 26, 2024, the appointment of Dr. Jonathan F. Miller as Chief Medical Officer. Dr. Miller previously served as Senior Vice President and Chief Medical Officer at Insmed Incorporated, where he was instrumental in the development of ARIKAYCE. His appointment is expected to bolster Cartesian's clinical development strategy.
Why It Matters
The appointment of a new Chief Medical Officer with a strong track record in drug development can signal a company's renewed focus and potential for advancing its pipeline, impacting investor confidence.
Risk Assessment
Risk Level: medium — The appointment of a new executive is a significant event that could impact the company's strategic direction and future performance.
Key Players & Entities
- Cartesian Therapeutics, Inc. (company) — Registrant
- Jonathan F. Miller (person) — Newly appointed Chief Medical Officer
- Insmed Incorporated (company) — Former employer of Dr. Miller
- ARIKAYCE (drug) — Drug developed under Dr. Miller's leadership
FAQ
Who has been appointed as the new Chief Medical Officer of Cartesian Therapeutics, Inc.?
Dr. Jonathan F. Miller has been appointed as the new Chief Medical Officer of Cartesian Therapeutics, Inc.
When was the appointment of the new Chief Medical Officer announced?
The appointment was announced on March 26, 2024.
What was Dr. Jonathan F. Miller's previous role?
Dr. Miller's previous role was Senior Vice President and Chief Medical Officer at Insmed Incorporated.
What drug was Dr. Miller instrumental in developing at Insmed?
Dr. Miller was instrumental in the development of ARIKAYCE at Insmed Incorporated.
What is the address of Cartesian Therapeutics, Inc.'s principal executive offices?
The address of Cartesian Therapeutics, Inc.'s principal executive offices is 704 Quince Orchard Road, Gaithersburg, MD 20878.
Filing Stats: 1,375 words · 6 min read · ~5 pages · Grade level 11.2 · Accepted 2024-04-01 16:32:42
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC Ind
- $420,000 — led to receive an annual base salary of $420,000, and will be eligible for an annual per
- $440,000 — led to receive an annual base salary of $440,000 and will be eligible for an annual perf
Filing Documents
- rnac-20240326.htm (8-K) — 38KB
- exhibit101employmentagreem.htm (EX-10.1) — 146KB
- exhibit102employmentagreem.htm (EX-10.2) — 139KB
- 0001453687-24-000052.txt ( ) — 499KB
- rnac-20240326.xsd (EX-101.SCH) — 2KB
- rnac-20240326_lab.xml (EX-101.LAB) — 21KB
- rnac-20240326_pre.xml (EX-101.PRE) — 12KB
- rnac-20240326_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description 10.1 Employment Agreement, dated as of March 26, 2024, by and between the Registrant and Christopher Jewell, Ph.D. 10.2 Employment Agreement, dated as of March 28, 2024, by and between the Registrant and Metin Kurtoglu, M.D., Ph.D. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARTESIAN THERAPEUTICS, INC. Date: April 1, 2024 By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer